| |
Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.....CDC....Hepatitis C Deaths Up Sharply Over Past Decade
|
| |
| |
Download the PDF here
Clinical Infectious Diseases Advance Access published March 17, 2016
Kathleen N. Ly, Elizabeth M. Hughes, Ruth B. Jiles,, and Scott D. Holmberg
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia
By Gina Shaw
Deaths related to hepatitis C virus (HCV) in the United States jumped from 11,051 in 2003 to 19,368 in 2013, according to the Centers for Disease Control and Prevention (CDC) (Clin Infect Dis 2016 Mar 1. [Epub ahead of print]). During the same period, deaths associated with 59 other notifiable infectious diseases, including HIV, Staphylococcus aureus, hepatitis B, tuberculosis and pneumococcal disease, decreased from a total of 24,434 in 2003 to 18,002 in 2013, the CDC said.
Because of new novel therapies that cure HCV, the statistics might surprise some. However, the new therapies will not affect death rates for years to come. Over the past 10 years, there has been an increasing number of aging baby boomers who have been living with untreated or suboptimally treated HCV, who have developed advanced liver disease and liver cancer. Those are the individuals who have been contributing to the increased death rates from HCV-related causes. In patients with decompensated cirrhosis or liver cancer, as many of these patients have, new therapies may cure their HCV, but they can't cure their cancer. In addition, the study period only goes to 2013-the year sofosbuvir (Sovaldi, Gilead Sciences) was approved, according to said Jonathan Fenkel, MD, the director of the Hepatitis C Center at Thomas Jefferson University Hospital in Philadelphia, who was asked to comment on the findings.
More than half (51%) of the deaths occurred among adults 55 to 64 years of age. [73% of HCV Related Deaths in ages 45-54 & 55-64]
"This is the Baby Boom generation, people who became infected with hepatitis C in the 1960s and 1970s, who have had chronic liver disease for 30 years," Dr. Fenkel said in an interview with SPC. "Even if those patients can get cured now with the new direct-acting antivirals, many of them still have cirrhosis and liver cancer related to their hepatitis C."
Dr. Fenkel, who was asked to comment on the findings, but was not part of the study, noted that the advent of novel HCV drugs such as sofosbuvir, ledipasvir-sofosbuvir (Harvoni, Gilead Sciences) and elbasvir-grazoprevir (Zepatier, Merck) may offer an opportunity for some patients with advanced liver disease to reverse that damage.
"Historically, I would have said that if you have scarring on your liver, it doesn't go away. But now there are some data coming out of Europe indicating that maybe 50% of patients with cirrhosis can have it reversed after being cured of their hepatitis C. Now, it's still not clear if that reduces their risk of liver cancer; we will need longer-term data from that. And in more than half of patients with decompensated cirrhosis, even if you cure their hepatitis C, they will still need a liver transplant."
Dr. Fenkel predicted that HCV deaths will remain elevated for at least the next five years, and maybe a bit longer. "After about five to 10 years, we should start to see a decline after the people we are treating now become part of the statistics. Those we treat now, who don't yet have cirrhosis, we should be able to prevent most of them from dying of hepatitis C-related causes."
--------------------
"Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013"
HCV Death Rates Doubled Predominantly Among Middle-Aged People BUT its Underestimated because HCV usually NOT listed on death certificates....
73% of HCV Related Deaths in ages 45-54 & 55-64 CDC
"There are many putative reasons why there remains underappreciation of the seriousness of HCV infection: the decades-long asymptomatic incubation period that may make clinicians and patients discount the importance of the infection; the lack of cohesive and vocal advocacy groups as many patients were former injection drug users; "compassion fatigue" from HIV/AIDS and other large acute public health problems; and, currently, a new therapeutic nihilism not about the efficacy of antivirals but about their perceived cost, despite evident cost-effectiveness"
"In 2007, the greatest proportion of HBV- and HCV-related deaths was among persons aged 45 to 54 and 55 to 64 years; 59.4% of HBV-related deaths and 73.4% of HCV-related deaths occurred in these relatively young age groups [CDC Annals on Int Med 2012: http://www.natap.org/2012/HCV/022212_02.htm
Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.....avg annual increase 3.4% HCV mortality rate almost doubled from 3.72/100,000 to 5.03/100,000......"Data from our study and from previous analyses showed that HCV-related deaths occurred mainly among those aged 55-64 years"....."analysis of approximately 1600 well-characterized HCV-infected patients in the United States who died found that only 19% of them had HCV listed anywhere on their death certificate"....."Even among HCV-infected patients whose death certificate listed a liver-related cause of death, 59% did not have HCV listed as a cause of death [10]. Therefore, we believe these data greatly underestimate the true hepatitis C mortality burden."
..."One explanation for the increasing HCV-related mortality could be that many HCV-infected persons are not receiving antiviral therapy and achieving a sustained virologic response indicative of a cure. In fact, one study found that only 19% of HCV and 16% of HCV/HIV-coinfected patients were eligible for and advanced to treatment [9]. Furthermore, only 13% and 11%, respectively, completed treatment and 3% and 6%, respectively, achieved a sustained virology response"
Clin Infect Dis. March 1 (2016)
Abstract
In the United States, hepatitis C virus (HCV)-associated mortality is increasing. From 2003-2013, the number of deaths associated with HCV has now surpassed 60 other nationally notifiable infectious conditions combined. The increasing HCV-associated mortality trend underscores the urgency in finding, evaluating, and treating HCV-infected persons.
- From 2003 to 2013, the number of deaths associated with hepatitis C listed on death certificates increased from 11 051 in 2003 to 19 368 in 2013
- These deaths represented an average annual increase of 865 deaths per year, and the average annual percentage increase was 6.2% (P < .05)
- In comparison, the number of deaths associated with ONNICs [other major diseases], 60 conditions in all, decreased from 24 745 in 2003 to 17 915 in 2013 (see Supplementary Appendix for listing of deaths in 2013 by specific infectious condition). These deaths represented an average annual decrease of 718 deaths per year (Figure 1), and the average annual percentage decrease was 3.4% (P < .05).....mostly due to a decline in human immunodeficiency virus (HIV)-related deaths, and, to a lesser extent, a decline in pneuomococcal disease-related and tuberculosis-related deaths. The number of HIV-related deaths declined by 41.8% from 15 168 deaths in 2003 to 8831 deaths in 2013. Pneumococcal disease-related deaths decreased by 31.0%
- In 2012, hepatitis C mortality rate, as opposed to the crude number of deaths, associated with hepatitis C increased from 3.72 (95% CI, 3.65-3.79) deaths per 100 000 population in 2003 to 5.03 (95% CI, 4.96-5.11) deaths per 100 000 population in 2013. These mortality rates represent an average annual increase of 0.14 deaths per 100 000 population per year, and the average annual percentage increase was 3.4% (P < .05).
Despite enthusiasm for the new curative, brief (12-week), all-oral antiviral treatments for hepatitis C virus (HCV) infection, the continued health burden [1] and increased mortality [2] for HCV-infected patients in the United States remain underappreciated. We examined national multiple-cause-of-death (MCOD) data from 2003 to 2013 to provide more current estimates of trends in hepatitis C-related mortality in the United States and compared these with trends in deaths associated with 60 other nationally notifiable infectious conditions (ONNICs) that are routinely reported to the Centers for Disease Control and Prevention (CDC).
METHODS
Death certificate information from the public-use MCOD data, obtained from the National Center for Health Statistics, was examined. Mortality codes for 2 disease categories, hepatitis C and ONNICs, as classified by the International Classification of Diseases, 10th Revision (ICD-10) [3], were examined. Deaths associated with hepatitis C were defined as having the ICD-10 codes B17.1 and B18.2 listed in the "record axis" MCOD fields. Deaths associated with ONNICs [4] were defined as having any of the ICD-10 codes associated with 60 conditions (see Supplementary Appendix) recorded in the "record axis" MCOD fields. To ensure mutual exclusivity between the 2 disease categories, any ONNIC-related death that also had a listing of hepatitis C was excluded from the ONNICs category, which was, on average, 1067 deaths (range, 936-1193) per year.
To calculate mortality rates, the number of deaths associated with HCV infection and ONNICs were divided by the total US census population for each year and then adjusted to the age distribution of the standard US population in 2000 by using the direct method [5]. Ninety-five percent confidence intervals (CIs) were calculated based on the gamma distribution to estimate the variance [6]. Trends in age-adjusted mortality rates were analyzed using joinpoint regression [7]. The resulting trends were described by the slope of the line segment or annual percentage change by applying the least-squares linear regression method.
RESULTS
From 2003 to 2013, the number of deaths associated with hepatitis C listed on death certificates increased from 11 051 in 2003 to 19 368 in 2013 (Figure 1). These deaths represented an average annual increase of 865 deaths per year, and the average annual percentage increase was 6.2% (P < .05). In comparison, the number of deaths associated with ONNICs, 60 conditions in all, decreased from 24 745 in 2003 to 17 915 in 2013 (see Supplementary Appendix for listing of deaths in 2013 by specific infectious condition).
These deaths represented an average annual decrease of 718 deaths per year (Figure 1), and the average annual percentage decrease was 3.4% (P < .05). The decline in ONNIC-related deaths was mostly due to a decline in human immunodeficiency virus (HIV)-related deaths, and, to a lesser extent, a decline in pneuomococcal disease-related and tuberculosis-related deaths. The number of HIV-related deaths declined by 41.8% from 15 168 deaths in 2003 to 8831 deaths in 2013. Pneumococcal disease-related deaths decreased by 31.0% from 1283 deaths in 2003 to 885 deaths in 2013; tuberculosis-related deaths decreased by 28.2% from 1382 deaths in 2003 to 992 deaths in 2013. When combined, these 3 conditions were associated with a 39.9% decline from 17 764 deaths in 2003 to 10 683 deaths in 2013.
In 2012, the number of deaths associated with hepatitis C surpassed that of 60 ONNICs that are routinely reported to CDC (Figure 1). The mortality rate, as opposed to the crude number of deaths, associated with hepatitis C increased from 3.72 (95% CI, 3.65-3.79) deaths per 100 000 population in 2003 to 5.03 (95% CI, 4.96-5.11) deaths per 100 000 population in 2013. These mortality rates represent an average annual increase of 0.14 deaths per 100 000 population per year, and the average annual percentage increase was 3.4% (P < .05). In comparison, the mortality rate associated with ONNICs decreased from 8.51 (95% CI, 8.41-8.62) deaths per 100 000 population in 2003 to 5.25 (95% CI, 5.17-5.33) deaths per 100 000 population in 2013. These mortality rates represented an average annual decrease of 0.34 deaths per 100 000 population per year, and the average annual percentage decrease was 4.9% (P < .05). In 2013, 51.1% (n = 9899) of HCV-related deaths occurred among persons aged 55-64 years (mean age, 59.7 years).
DISCUSSION
Despite improving therapies [8], our study found that deaths associated with HCV continued to rise while deaths associated with 60 ONNICs that are routinely reported to CDC declined. The great decline among deaths associated with HIV, pneumococcal disease, and tuberculosis from the ONNICs category were likely due to implementation of effective public health programs and policies.
One explanation for the increasing HCV-related mortality could be that many HCV-infected persons are not receiving antiviral therapy and achieving a sustained virologic response indicative of a cure. In fact, one study found that only 19% of HCV and 16% of HCV/HIV-coinfected patients were eligible for and advanced to treatment [9]. Furthermore, only 13% and 11%, respectively, completed treatment and 3% and 6%, respectively, achieved a sustained virologic response [9]. Data from our study and from previous analyses showed that HCV-related deaths occurred mainly among those aged 55-64 years [2], indicating the premature loss of life and economic burden with HCV infection. The largest extant analysis of approximately 1600 well-characterized HCV-infected patients in the United States who died found that only 19% of them had HCV listed anywhere on their death certificate, although 75% had premortem indications of substantial or extensive liver disease at time of death [10]. Even among HCV-infected patients whose death certificate listed a liver-related cause of death, 59% did not have HCV listed as a cause of death [10]. Therefore, we believe these data greatly underestimate the true hepatitis C mortality burden.
There are many putative reasons why there remains underappreciation of the seriousness of HCV infection, an infection among an estimated 3.2 million US residents [1], and continuing deficiencies in the decades-long asymptomatic incubation period that may make clinicians and patients discount the importance of the infection; the lack of cohesive and vocal advocacy groups as many patients were former injection drug users; "compassion fatigue" from HIV/AIDS and other large acute public health problems; and, currently, a new therapeutic nihilism not about the efficacy of antivirals but about their perceived cost, despite evident cost-effectiveness [12]. The unabated increasing trend in the number of hepatitis C-related deaths documented from 1999 to 2013, predominantly among middle-aged persons, underscores the urgency in finding, evaluating, and treating patients in the largest infectious disease epidemic in the United States.
|
|
| |
| |
|
|
|
